OBSV News and Press, ObsEva SA From 03/09/21

ObsEva ([[OBSV]] +9.3%) has entered into a sales agreement with SVB Leerink to sell the common stock for total gross proceeds of up to $50M, the company has said in a regulatory filing.SVB Leerink will be the sales agent for at the market offering where the company expects to sell the co...

ObsEva (OBSV): Q4 GAAP EPS of -$0.32 beats by $0.12.Cash and cash equivalents of $31.2MPress Release For further details see: ObsEva EPS beats by $0.12

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study ...

Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corpo...

Gainers: [[RNWK]] +14.1%. [[VIOT]] +8%. [[IMUX]] +7.5%. [[CRVS]] +6.4%. [[OTIC]] +4.4%.Losers: [[PT]] -4.7%. [[OBSV]] -2.8%. [[PETS]] -2.6%. [[EVGN]] -2%. [[EOLS]] -1.7%. For further details see: PETS, IMUX, EVGN and OTIC among after-hours movers

Shares of women's reproductive health company ObsEva SA (OBSV) are up 9.2% to $4.33 in morning trading.An article published in TipRanks yesterday listed Switzerland-based ObsEva as one of two stocks that could rally more than 100%.Author Michael Marcus wrote that the company's lead ...

Today, the stock market is back in a bull mode as the Dow, S&P, and Nasdaq are all pointing toward a higher morning session. Of course, after a bit of a drought over the last few days, traders are now seeking opportunities, and penny stocks could be one area of focus. Something to keep ...

Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Manageme...

GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided a corporate update, including its roadmap for...

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions. A look back at companies I have written articles about over the last three years - 2018-2020. The good, the bad and the ugly! For further details see: Fin...